SKYE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
12/20/2025 07:39 AM • A securities class action has been filed against Skye Bioscience after the company announced that its drug nimacimab failed to meet primary endpoints in a Phase 2a clinical trial on October 6, 2025. The announcement revealed lower-than-expected drug exposure, causing the stock to plummet 60% from $4.75 to $1.90 per share. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to contact the law firm, with a January 16, 2026 deadline to seek lead plaintiff status.
SKYE - The company failed to achieve primary endpoints in a Phase 2a clinical trial for its lead drug candidate nimacimab, revealed lower-than-expected drug exposure, and experienced a 60% stock price decline. These developments have triggered a federal securities class action lawsuit alleging false and misleading statements about the drug's effectiveness and commercial prospects.